Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Overman on Next Steps With Immunotherapy in mCRC

December 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.

Dr. Lenz on Potential for Immunotherapy in mCRC

December 20th 2018

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.

Dr. Bekaii-Saab on Challenges With Precision Medicine in CRC

December 19th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.

Dr. Benson on Considerations for Advanced CRC Treatment

December 12th 2018

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the factors to consider when approaching treatment for a patient with advanced colorectal cancer.

Dr. Strickler on the Importance of Molecular Markers in mCRC

December 6th 2018

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses improvements in the treatment of metastatic colorectal cancer.

GI Cancer Treatment Continues to Evolve, But Unmet Needs Remain

December 1st 2018

Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.

Dr. O'Connor Discusses Regorafenib Dosing in mCRC

November 30th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Tumor Mutational Burden in CRC

November 21st 2018

Efficacy and Safety of Immunotherapy for mCRC

November 21st 2018

TAS-102 Versus Regorafenib for Treating mCRC

November 21st 2018

Sidedness as Drivers of Treatment Decisions in CRC

November 21st 2018

Treatment Options for Right-Sided CRC

November 21st 2018

Treatment Options for First- and Second-Line Left-Sided CRC

November 21st 2018

Optimal Therapy for BRAF-Mutated mCRC

November 21st 2018

Application of Molecular Testing Results in Treating mCRC

November 21st 2018

Molecular Testing for Newly Diagnosed mCRC

November 21st 2018

Treating Locally Advanced Rectal Cancer

November 21st 2018

Maintaining Wellness After Treatment

November 21st 2018

Optimal Duration of Therapy for Stage III Colon Cancer

November 21st 2018

Treatment Options for High-Risk Stage II Colon Cancer

November 21st 2018